WO2008127456A3 - Compositions for the reversal and detoxification of anesthetics and other compounds and methods of their use - Google Patents
Compositions for the reversal and detoxification of anesthetics and other compounds and methods of their use Download PDFInfo
- Publication number
- WO2008127456A3 WO2008127456A3 PCT/US2007/086642 US2007086642W WO2008127456A3 WO 2008127456 A3 WO2008127456 A3 WO 2008127456A3 US 2007086642 W US2007086642 W US 2007086642W WO 2008127456 A3 WO2008127456 A3 WO 2008127456A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- anesthetics
- methods
- attenuating
- toxins
- drugs
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases, cochleates; Sponge phases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07873662A EP2107904A4 (en) | 2006-12-07 | 2007-12-06 | Compositions for the reversal and detoxification of anesthetics and other compounds and methods of their use |
JP2009540476A JP2010512341A (en) | 2006-12-07 | 2007-12-06 | Compositions for reversal and detoxification of anesthetics and other compounds and methods of use thereof |
AU2007351338A AU2007351338B2 (en) | 2006-12-07 | 2007-12-06 | Compositions for the reversal and detoxification of anesthetics and other compounds and methods of their use |
CA2672024A CA2672024C (en) | 2006-12-07 | 2007-12-06 | Compositions for the reversal and detoxification of anesthetics and other compounds and methods of their use |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US86895006P | 2006-12-07 | 2006-12-07 | |
US60/868,950 | 2006-12-07 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008127456A2 WO2008127456A2 (en) | 2008-10-23 |
WO2008127456A3 true WO2008127456A3 (en) | 2008-12-11 |
Family
ID=39864561
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/086642 WO2008127456A2 (en) | 2006-12-07 | 2007-12-06 | Compositions for the reversal and detoxification of anesthetics and other compounds and methods of their use |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP2107904A4 (en) |
JP (1) | JP2010512341A (en) |
AU (1) | AU2007351338B2 (en) |
CA (1) | CA2672024C (en) |
WO (1) | WO2008127456A2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2871821C (en) * | 2012-05-10 | 2021-01-12 | Painreform Ltd. | Depot formulations of a local anesthetic and methods for preparation thereof |
JP6255975B2 (en) * | 2012-12-27 | 2018-01-10 | Jnc株式会社 | Liquid crystal composition, antioxidant and liquid crystal display element |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5922317A (en) * | 1996-01-04 | 1999-07-13 | The United States Of America As Represented By The Secretary Of The Navy | Accelerated gas removal from divers' tissues utilizing gas metabolizing bacteria |
WO2001022960A1 (en) * | 1999-09-30 | 2001-04-05 | Charlotte-Mecklenburg Hospital Authority Doing Business As Carolinas Medical Center | Treatment of carbon monoxide poisoning |
US20030133877A1 (en) * | 1997-07-21 | 2003-07-17 | Levin Bruce H. | Apparatus for directed intranasal administration of a composition |
US20040143021A1 (en) * | 2003-01-21 | 2004-07-22 | Larijani Ghassem E. | Compositions and methods for improving recovery after general anesthesia |
WO2005034872A2 (en) * | 2003-10-08 | 2005-04-21 | Lyotropic Therapeutics, Inc. | Drug-delivery vehicles based on reversed liquid crystalline phase materials |
US20050101621A1 (en) * | 2003-11-12 | 2005-05-12 | Richard Lipsky | Method for rapid detoxification of addiction |
US20050119340A1 (en) * | 2003-06-13 | 2005-06-02 | David Anderson | Treatment methods with low-dose, longer-acting formulations of local anesthetics and other agents |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999012640A1 (en) * | 1997-09-09 | 1999-03-18 | Select Release, L.C. | Coated particles, methods of making and using |
US20030232340A1 (en) * | 2002-06-13 | 2003-12-18 | David Anderson | Nanoporous particle with a retained target |
CA2488705A1 (en) * | 2002-06-13 | 2003-12-24 | Lyotropic Therapeutics, Inc. | A nanoporous particle with a retained target |
-
2007
- 2007-12-06 CA CA2672024A patent/CA2672024C/en active Active
- 2007-12-06 EP EP07873662A patent/EP2107904A4/en not_active Withdrawn
- 2007-12-06 WO PCT/US2007/086642 patent/WO2008127456A2/en active Application Filing
- 2007-12-06 AU AU2007351338A patent/AU2007351338B2/en active Active
- 2007-12-06 JP JP2009540476A patent/JP2010512341A/en active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5922317A (en) * | 1996-01-04 | 1999-07-13 | The United States Of America As Represented By The Secretary Of The Navy | Accelerated gas removal from divers' tissues utilizing gas metabolizing bacteria |
US20030133877A1 (en) * | 1997-07-21 | 2003-07-17 | Levin Bruce H. | Apparatus for directed intranasal administration of a composition |
WO2001022960A1 (en) * | 1999-09-30 | 2001-04-05 | Charlotte-Mecklenburg Hospital Authority Doing Business As Carolinas Medical Center | Treatment of carbon monoxide poisoning |
US20040143021A1 (en) * | 2003-01-21 | 2004-07-22 | Larijani Ghassem E. | Compositions and methods for improving recovery after general anesthesia |
US20050119340A1 (en) * | 2003-06-13 | 2005-06-02 | David Anderson | Treatment methods with low-dose, longer-acting formulations of local anesthetics and other agents |
WO2005034872A2 (en) * | 2003-10-08 | 2005-04-21 | Lyotropic Therapeutics, Inc. | Drug-delivery vehicles based on reversed liquid crystalline phase materials |
US20050101621A1 (en) * | 2003-11-12 | 2005-05-12 | Richard Lipsky | Method for rapid detoxification of addiction |
Non-Patent Citations (1)
Title |
---|
See also references of EP2107904A4 * |
Also Published As
Publication number | Publication date |
---|---|
JP2010512341A (en) | 2010-04-22 |
EP2107904A2 (en) | 2009-10-14 |
AU2007351338B2 (en) | 2013-04-04 |
CA2672024C (en) | 2014-07-08 |
EP2107904A4 (en) | 2010-06-02 |
AU2007351338A1 (en) | 2008-10-23 |
WO2008127456A2 (en) | 2008-10-23 |
CA2672024A1 (en) | 2008-10-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2014144130A3 (en) | Pharmaceutical composition comprising an ampk activator and a serotonergic agent and methods of use thereof | |
WO2011053792A3 (en) | Methods and compositions for sustained delivery of drugs | |
BRPI0906181A2 (en) | "method for treating hyperproliferative dysfunction, pharmaceutical composition, use of a therapeutic combination in the manufacture of a medicament for treating cancer, article of manufacture for treating a hyperproliferative dysfunction, method for determining compounds to be used in combination for the treatment of cancer". cancer treatment and method for determining a therapeutic combination to be used for cancer treatment " | |
GEP20125628B (en) | Pharmaceutical compositions containing antagonist anti-cd40 antibody | |
WO2013158680A3 (en) | Compositions and methods comprising celecoxib or related compounds and dextromethorphan | |
ECSP13012618A (en) | DERIVATIVES OF 2,3-DIHYDROIMIDAZO [1,2-C] QUINAZOLINA SUBSTITUTED WITH AMINOALCOHOLES THAT ARE USEFUL TO TREAT HYPERPROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | |
EA200701195A1 (en) | CONTAINING CEFALOSPORIN COMPOSITIONS WITH NANOPARTICLES AND WITH CONTROLLED DELIVERY | |
WO2008054454A3 (en) | Nitrogen-containing heterocycle derivatives, pharmaceutical compositions, and methods of use thereof as antiviral agents | |
AR070834A1 (en) | DOSAGE AND FORMULATION OF ACLIDINIO FOR THE TREATMENT OF RESPIRATORY DISORDERS | |
WO2007100675A3 (en) | Collagenase for treating cellulite | |
WO2009043987A9 (en) | Antibiotic compositions containing essential oils, prophylaxis and treatment of nosocomial diseases | |
WO2007046083A3 (en) | Compositions for treatment of eye diseases | |
WO2006017188A3 (en) | Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients | |
HK1125039A1 (en) | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain | |
WO2006098603A3 (en) | Composition comprising isoorientin for suppressing histamine | |
WO2007112272A3 (en) | Formulations of low dose diclofenac and beta-cyclodextrin | |
WO2008112773A3 (en) | Droxidopa and pharmaceutical composition thereof for the treatment of neurally mediated hypotension | |
WO2010129962A3 (en) | Combination treatment of hydroxypyridonate actinide/lanthanide decorporation agents | |
AU2009246603A8 (en) | Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction | |
WO2008012796A3 (en) | Pharmaceutical compositions comprising ccl2 and use of same for the treatment of inflammation | |
WO2015035410A8 (en) | Cancer therapy | |
WO2008070010A3 (en) | Hydroxylamine derivatives for the treatment of stroke | |
GB2456475A (en) | Composition for the treatment of skin conditions | |
WO2008127456A3 (en) | Compositions for the reversal and detoxification of anesthetics and other compounds and methods of their use | |
CO6220945A2 (en) | USE OF A COMPOSITION THAT INCLUDES FORMOTEROL AND DIPROPIANATE OF BECLOMETASONE FOR THE PREVENTION AND / OR TREATMENT OF AN EXAMERATION OF ASTHMA |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07873662 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007351338 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2009540476 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2672024 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2007351338 Country of ref document: AU Date of ref document: 20071206 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007873662 Country of ref document: EP |